Skip to main content

Table 3 Subgroup analysis and sensitivity analyses of FEV1 and ACQ-5 scores in RCTs

From: Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials

Stratification Subgroup analysis FEV1 ACQ-5 scores
No. of Patients (trials) SMD (95% CI) P Value I2, % No. of Patients (trials) SMD (95% CI) P Value I2, %
Effects model
 Random-effects model 3218 (7) 4.29 (2.78 to 5.81) < 0.001 99 2670 (4) −4.95(−7.30 to −2.60) < 0.001 100
 Fixed effects model 3218 (7) 4.48 (4.32 to 4.62) < 0.001 99 2670 (4) −4.24(− 4.40 to − 4.09) < 0.001 100
Region of study
 The US 104 (1) 4.47 (3.74 to 5.20) < 0.001 104 (1) −4.53(−5.26 to −3.79) < 0.001
 Multinational 3114 (6) 4.31 (2.85 to 5.97) < 0.001 99 2566 (3) −5.09(−7.29 to −2.25) < 0.001 100
No. of subjects
 <  150 651 (4) 3.21 (1.98 to 4.43) < 0.001 96 104 (1) −4.53(−5.26 to −3.79) < 0.001
 ≥150 2567 (3) 5.80 (3.86 to 7.74) < 0.001 99 2566 (3) −5.09(−7.29 to −2.25) < 0.001 100
Treatment duration
 <  50 weeks 1316 (4) 3.35 (2.36 to 4.34) < 0.001 96 768 (2) −3.47(−5.48 to −1.46) < 0.001 96
 ≥50 weeks 1902 (2) 6.74 (6.25 to 7.23) < 0.001 77 1902 (2) −6.39(−9.89 to −2.89) < 0.001 100
Blood eosinophil count
 <  300 eosinophils per μl 1536 (5) 5.56 (2.59 to 8.53) < 0.001 99 388 (1) −1.80(−2.08 to − 1.52) < 0.001
 ≥300 eosinophils per μl 1269 (4) 2.05 (0.97 to 3.12) < 0.001 98 380 (2) −2.43(−6.52 to − 1.66) < 0.001 99
Sources of funding
 Pharmaceutical company   4.29 (2.78 to 5.81) < 0.001 99   −4.95(−7.30 to −2.60) < 0.001 100
 Non-pharmaceutical company 0 (0)
  1. Abbreviations: FEV1 forced expiratory volume in 1 s, ACQ-5 5-item Asthma Control Questionnaire